Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study
Objectives: Atrial fibrillation (AF) is characterized by an oxidative imbalance, which is associated with an increased risk of cardiovascular events (CVEs). It is unclear whether low grade endotoxemia may contribute to the impaired antioxidant status in AF patients. We investigated the relationship...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.779503/full |
| _version_ | 1818750927361802240 |
|---|---|
| author | Danilo Menichelli Roberto Carnevale Roberto Carnevale Cristina Nocella Cristina Nocella Vittoria Cammisotto Valentina Castellani Simona Bartimoccia Giacomo Frati Giacomo Frati Pasquale Pignatelli Pasquale Pignatelli Daniele Pastori |
| author_facet | Danilo Menichelli Roberto Carnevale Roberto Carnevale Cristina Nocella Cristina Nocella Vittoria Cammisotto Valentina Castellani Simona Bartimoccia Giacomo Frati Giacomo Frati Pasquale Pignatelli Pasquale Pignatelli Daniele Pastori |
| author_sort | Danilo Menichelli |
| collection | DOAJ |
| description | Objectives: Atrial fibrillation (AF) is characterized by an oxidative imbalance, which is associated with an increased risk of cardiovascular events (CVEs). It is unclear whether low grade endotoxemia may contribute to the impaired antioxidant status in AF patients. We investigated the relationship between circulating lipopolysaccharides (LPS) and antioxidant status in AF patients.Patients and Methods:Post-hoc analysis from the ongoing prospective observational cohort ATHERO-AF study including 907 patients. Antioxidant status was evaluated by the activity of glutathione peroxidase 3 (GPx3) and superoxide dismutase (SOD). Patients were divided into two groups to evaluate the risk of CVEs: (1) LPS below median and GPx3 above median (n = 254); (2) LPS above median and GPx3 below median (n = 263).Results: The mean age was 73.5 ± 8.3 years, and 43.1% were women. Median LPS and GPx3 were 50.0 pg/ml [interquartile range (IQR) 15–108] and 20.0 U/ml (IQR 10.0–34.0), respectively. Patients of Groups 2 were older, with a higher prevalence of heart failure. LPS above the median was associated with reduced GPx3 [Odds Ratio for LPS 1.752, 95% Confidence Interval (CI) 1.344–2.285, p < 0.001] and SOD (OR 0.525, 95%CI 0.403–0.683) activity after adjustment for CHA2DS2VASc score. In a mean follow-up of 54.0 ± 36.8 months, 118 CVEs occurred, 42 in Group 1 and 76 in Group 2 (Log-Rank test p = 0.001). At multivariable Cox regression analysis, Group 2 was associated with a higher risk of CVEs [Hazard Ratio (HR) 1.644, 95%CI 1.117–2,421, p = 0.012], along with age ≥ 75 years (HR 2.035, 95%CI 1.394–2.972, p < 0.001), diabetes (HR 1.927, 95%CI 1.280–2.900, p = 0.002), and previous cerebrovascular disease (HR 1.895, 95%CI 1.251–2.870, p = 0.003) and previous cardiovascular disease (HR 1.708, 95%CI 1.149–2.538, p = 0.008).Conclusions: Our study indicates that circulating LPS may contribute to impaired antioxidant status in patients with AF. Patients with coincidentally high LPS and reduced GPx3 activity showed the highest risk of CVEs. |
| first_indexed | 2024-12-18T04:27:27Z |
| format | Article |
| id | doaj.art-9941436355da4b80bcc37ae8e215ba38 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-18T04:27:27Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-9941436355da4b80bcc37ae8e215ba382022-12-21T21:21:04ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2021-11-01810.3389/fcvm.2021.779503779503Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF StudyDanilo Menichelli0Roberto Carnevale1Roberto Carnevale2Cristina Nocella3Cristina Nocella4Vittoria Cammisotto5Valentina Castellani6Simona Bartimoccia7Giacomo Frati8Giacomo Frati9Pasquale Pignatelli10Pasquale Pignatelli11Daniele Pastori12Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Angio-Cardio-Neurology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, Località Camerelle, Pozzilli, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Angio-Cardio-Neurology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, Località Camerelle, Pozzilli, ItalyDepartment of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, ItalyDepartment of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, ItalyDepartment of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, ItalyDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Angio-Cardio-Neurology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, Località Camerelle, Pozzilli, ItalyDepartment of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, ItalyMediterranea Cardiocentro, Naples, ItalyDepartment of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, ItalyObjectives: Atrial fibrillation (AF) is characterized by an oxidative imbalance, which is associated with an increased risk of cardiovascular events (CVEs). It is unclear whether low grade endotoxemia may contribute to the impaired antioxidant status in AF patients. We investigated the relationship between circulating lipopolysaccharides (LPS) and antioxidant status in AF patients.Patients and Methods:Post-hoc analysis from the ongoing prospective observational cohort ATHERO-AF study including 907 patients. Antioxidant status was evaluated by the activity of glutathione peroxidase 3 (GPx3) and superoxide dismutase (SOD). Patients were divided into two groups to evaluate the risk of CVEs: (1) LPS below median and GPx3 above median (n = 254); (2) LPS above median and GPx3 below median (n = 263).Results: The mean age was 73.5 ± 8.3 years, and 43.1% were women. Median LPS and GPx3 were 50.0 pg/ml [interquartile range (IQR) 15–108] and 20.0 U/ml (IQR 10.0–34.0), respectively. Patients of Groups 2 were older, with a higher prevalence of heart failure. LPS above the median was associated with reduced GPx3 [Odds Ratio for LPS 1.752, 95% Confidence Interval (CI) 1.344–2.285, p < 0.001] and SOD (OR 0.525, 95%CI 0.403–0.683) activity after adjustment for CHA2DS2VASc score. In a mean follow-up of 54.0 ± 36.8 months, 118 CVEs occurred, 42 in Group 1 and 76 in Group 2 (Log-Rank test p = 0.001). At multivariable Cox regression analysis, Group 2 was associated with a higher risk of CVEs [Hazard Ratio (HR) 1.644, 95%CI 1.117–2,421, p = 0.012], along with age ≥ 75 years (HR 2.035, 95%CI 1.394–2.972, p < 0.001), diabetes (HR 1.927, 95%CI 1.280–2.900, p = 0.002), and previous cerebrovascular disease (HR 1.895, 95%CI 1.251–2.870, p = 0.003) and previous cardiovascular disease (HR 1.708, 95%CI 1.149–2.538, p = 0.008).Conclusions: Our study indicates that circulating LPS may contribute to impaired antioxidant status in patients with AF. Patients with coincidentally high LPS and reduced GPx3 activity showed the highest risk of CVEs.https://www.frontiersin.org/articles/10.3389/fcvm.2021.779503/fullatrial fibrillationlipopolysaccharidesglutathione peroxidasesuperoxide dismutaseantioxidantgut |
| spellingShingle | Danilo Menichelli Roberto Carnevale Roberto Carnevale Cristina Nocella Cristina Nocella Vittoria Cammisotto Valentina Castellani Simona Bartimoccia Giacomo Frati Giacomo Frati Pasquale Pignatelli Pasquale Pignatelli Daniele Pastori Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study Frontiers in Cardiovascular Medicine atrial fibrillation lipopolysaccharides glutathione peroxidase superoxide dismutase antioxidant gut |
| title | Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study |
| title_full | Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study |
| title_fullStr | Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study |
| title_full_unstemmed | Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study |
| title_short | Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study |
| title_sort | circulating lipopolysaccharides and impaired antioxidant status in patients with atrial fibrillation data from the athero af study |
| topic | atrial fibrillation lipopolysaccharides glutathione peroxidase superoxide dismutase antioxidant gut |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2021.779503/full |
| work_keys_str_mv | AT danilomenichelli circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT robertocarnevale circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT robertocarnevale circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT cristinanocella circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT cristinanocella circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT vittoriacammisotto circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT valentinacastellani circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT simonabartimoccia circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT giacomofrati circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT giacomofrati circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT pasqualepignatelli circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT pasqualepignatelli circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy AT danielepastori circulatinglipopolysaccharidesandimpairedantioxidantstatusinpatientswithatrialfibrillationdatafromtheatheroafstudy |